Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 February 2013

Clinical Trials, Cohort Studies, Pilot Studies                              1 - 8                  

Basic and Applied Science, Pre-Clinical Studies              8 - 10

HIV/HCV Coinfection                                                              11 - 15

Epidemiology, Diagnostics & Miscellaneous Works                16 - 24

Liver Cancer                                                                              24 - 29

Clinical Trials, Cohort Studies, Pilot Studies

Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting.

Lloyd AR, Clegg J, Lange J, et l. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23362288

Exploratory study of oral combination antiviral therapy for hepatitis C. Poordad F, Lawitz E, Kowdley KV, et al. N Engl J Med. 2013 Jan 3;368(1):45-53. doi: 10.1056/NEJMoa1208809.

http://www.ncbi.nlm.nih.gov/pubmed/23281975

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. Gane EJ, Stedman CA, Hyland RH, Ding X, et al. N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.

http://www.ncbi.nlm.nih.gov/pubmed/23281974

Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. Seidenberg A, Rosemann T, Senn O. BMC Infect Dis. 2013 Jan 8;13(1):9. doi: 10.1186/1471-2334-13-9.

http://www.ncbi.nlm.nih.gov/pubmed/23298178

Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area. Chung HJ, Lee JW, Kim YS, Lee JI. Intervirology. 2013 Jan 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23306941

Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism. I-Shyan S, Chun-Yen L, Wen-Juei J, Chang-Wen H, Chien-Hao H, Ji-Yih C. Ann Hepatol. 2013 Jan;12(1):62-9.

http://www.ncbi.nlm.nih.gov/pubmed/23293195

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. Atsukawa M, Tsubota A, Kondo C, et al. J Gastroenterol Hepatol. 2013 Jan;28(1):51-6. doi: 10.1111/j.1440-1746.2012.07267.x.

http://www.ncbi.nlm.nih.gov/pubmed/22989264

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.

Kurosaki M, Tanaka Y, Nishida N, et al. J Med Virol. 2013 Mar;85(3):449-58. doi: 10.1002/jmv.23497. Epub 2013 Jan 7.

http://www.ncbi.nlm.nih.gov/pubmed/23297176

Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. Minisini R, Boccato E, Favretto S, et al. Alcohol Clin Exp Res. 2013 Jan 8. doi: 10.1111/acer.12047. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23298155

A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Oze T, Hiramatsu N, Mita E, et al. Hepatol Res. 2013 Jan;43(1):35-43. doi: 10.1111/j.1872-034X.2012.01056.x.

http://www.ncbi.nlm.nih.gov/pubmed/23332086

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Urquijo JJ, Diago M, Boadas J, et al. Ann Hepatol. 2013 Jan;12(1):30-5.

http://www.ncbi.nlm.nih.gov/pubmed/23293191

Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. Knop V, Bergk A, Schlosser B, et al. Eur J Gastroenterol Hepatol. 2013 Jan 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23325275

IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. Hsu CS, Hsu SJ, Liu WL, et al. Antivir Ther. 2013 Jan 7. doi: 10.3851/IMP2502. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23296193

Association of chronic liver disease with depression: a population-based study. Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM. Psychosomatics. 2013 Jan;54(1):52-9. doi: 10.1016/j.psym.2012.09.005.

http://www.ncbi.nlm.nih.gov/pubmed/23295007

Basic and Applied Science, Pre-Clinical Studies

Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation Factor VII gene expression. Suzuki A, Miyawaki Y, Okuyama E, et al. Biochem J. 2013 Jan 1;449(1):231-9. doi: 10.1042/BJ20121286.

http://www.ncbi.nlm.nih.gov/pubmed/23050902

A Synthetic Codon-Optimized Hepatitis C Virus Nonstructural 5A DNA Vaccine Primes Polyfunctional CD8+ T Cell Responses in Wild-Type and NS5A-Transgenic Mice.

Holmström F, Pasetto A, Nähr V, et al. J Immunol. 2013 Feb 1;190(3):1113-24. doi: 10.4049/jimmunol.1201497. Epub 2013 Jan 2.

http://www.ncbi.nlm.nih.gov/pubmed/23284053

Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Nitta S, Sakamoto N, Nakagawa M, et al. Hepatology. 2013 Jan;57(1):46-58. doi: 10.1002/hep.26017.

http://www.ncbi.nlm.nih.gov/pubmed/22911572

CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-jun N terminal kinase activation independent from the interferon pathway. Rau SJ, Hildt E, Himmelsbach K, et al. Hepatology. 2013 Jan;57(1):23-36. doi: 10.1002/hep.25966.

http://www.ncbi.nlm.nih.gov/pubmed/22814930

HIV/HCV Coinfection

Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients.

Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. AIDS Behav. 2013 Jan;17(1):94-103. doi: 10.1007/s10461-012-0288-9.

http://www.ncbi.nlm.nih.gov/pubmed/22907288

Sustained hcv clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Yu ML, Lee CM, Chen CL, et al. Hepatology. 2013 Jan 15. doi: 10.1002/hep.26266. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23322699

Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. Mandorfer M, Reiberger T, Payer BA, et al. AIDS. 2013 Jan 14;27(2):227-232.

http://www.ncbi.nlm.nih.gov/pubmed/23238552

Willingness to Undergo a Repeat Liver Biopsy Among HIV/Hepatitis C Virus-coinfected and Hepatitis C Virus-monoinfected Patients. Amorosa VK, Aibana O, Shire NJ, et al. J Clin Gastroenterol. 2013 Jan 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23328300

Rapid Progression to Decompensated Cirrhosis, Liver Transplant, and Death in HIV-Infected Men After Primary Hepatitis C Virus Infection. Fierer DS, Dieterich DT, Fiel MI, et al. Clin Infect Dis. 2013 Jan 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23264364

Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Kakinami L, Block RC, Adams MJ, Cohn SE, Maliakkal B, Fisher SG. Int J Clin Pract. 2013 Jan;67(1):6-13. doi: 10.1111/j.1742-1241.2012.02953.x.

http://www.ncbi.nlm.nih.gov/pubmed/23241046

Dualities of Living With HIV/HCV Co-Infection: Patients' Perspectives From Those who are Ineligible for or Nonresponsive to Treatment. Farrell G, Comiskey C. J Assoc Nurses AIDS Care. 2013 Jan 19. pii: S1055-3290(12)00251-8. doi: 10.1016/j.jana.2012.10.005. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23340239

Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons co-infected with HIV and hepatitis viruses. Andrade BB, Hullsiek KH, Boulware DR, et al. J Infect Dis. 2013 Jan 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23335804

Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Fernández-Rodríguez A, Rallón N, Berenguer J, et al. AIDS. 2013 Jan 14;27(2):163-73. doi: 10.1097/QAD.0b013e32835c11e8.

http://www.ncbi.nlm.nih.gov/pubmed/23135173

Antiretroviral Adherence Among Rural Compared to Urban Veterans with HIV Infection in the United States. Ohl ME, Perencevich E, McInnes DK, et al. AIDS Behav. 2013 Jan;17(1):174-80. doi: 10.1007/s10461-012-0325-8.

http://www.ncbi.nlm.nih.gov/pubmed/23080359

Epidemiology, Diagnostics, and Miscellaneous Works

Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Grebely J, Feld JJ, Applegate T, et al. Hepatology. 2013 Jan 16. doi: 10.1002/hep.26263. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23325615

Prognostic Gene-Expression Signature for Patients with Hepatitis C-Related Early-Stage Cirrhosis. Hoshida Y, Villanueva A, Sangiovanni A, et al. Gastroenterology. 2013 Jan 17. pii: S0016-5085(13)00078-4. doi: 10.1053/j.gastro.2013.01.021. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23333348

Hepatitis C virus infection in patients with primary biliary cirrhosis. Hsuan-Wei C, Hsin-Hung H, Ching-Huang L, et al. Ann Hepatol. 2013 Jan;12(1):78-84.

http://www.ncbi.nlm.nih.gov/pubmed/23293197

Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Ann Intern Med. 2013 Jan 15;158(2):101-8. doi: 10.7326/0003-4819-158-2-201301150-00574.

http://www.ncbi.nlm.nih.gov/pubmed/23183613

What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Hunt D, Pockros P. Curr Gastroenterol Rep. 2013 Jan;15(1):303. doi: 10.1007/s11894-012-0303-3.

http://www.ncbi.nlm.nih.gov/pubmed/23250703

The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries.

Vietri J, Prajapati G, El Khoury AC. BMC Gastroenterol. 2013 Jan 17;13:16. doi: 10.1186/1471-230X-13-16.

http://www.ncbi.nlm.nih.gov/pubmed/23324473

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. Talal AH, Lafleur J, Hoop R, et al. Aliment Pharmacol Ther. 2013 Feb;37(4):473-81. doi: 10.1111/apt.12200. Epub 2013 Jan 7.

http://www.ncbi.nlm.nih.gov/pubmed/23289640

Detection of hepatitis C virus transmission using DNA mass spectrometry. Ganova-Raeva LM, Dimitrova ZE, Campo DS, et al. J Infect Dis. 2013 Jan 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23300164

Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument. Szeinbach SL, Baran RW, Dietz B, Gazzouola Rocca L, Littlefield D, Yawn BP. Aliment Pharmacol Ther. 2013 Jan 7. doi: 10.1111/apt.12202. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23289740

Liver Fatty Acid Binding Protein Is a Diagnostic Marker to Detect Liver Injury as a Result of Chronic Hepatitis C Infection. Akbal E, Köklü S, Koçak E, et al. Arch Med Res. 2013 Jan 3. pii: S0188-4409(12)00335-9. doi: 10.1016/j.arcmed.2012.11.007. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23291381

Current prospects for interferon-free treatment of hepatitis C in 2012. Stedman CA. J Gastroenterol Hepatol. 2013 Jan;28(1):38-45. doi: 10.1111/jgh.12028.

http://www.ncbi.nlm.nih.gov/pubmed/23137126

Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? de Vos AS, van der Helm JJ, Matser A, Prins M, Kretzschmar ME. Addiction. 2013 Jan 24. doi: 10.1111/add.12125. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23347124

The Cobas AmpliPrep/Cobas TaqMan HCV Test, version 2.0 Real-time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA. Chevaliez S, Bouvier-Alias M, et al. J Clin Microbiol. 2013 Jan 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23325825

Viral genome analysis and knowledge management. Kuiken C, Yoon H, Abfalterer W, Gaschen B, Lo C, Korber B. Methods Mol Biol. 2013;939:253-61. doi: 10.1007/978-1-62703-107-3_16.

http://www.ncbi.nlm.nih.gov/pubmed/23192551

Association of tattooing and hepatitis C virus infection: A multicenter case-control study.

Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Hepatology. 2013 Jan 12. doi: 10.1002/hep.26245. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23315899

A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care.

McGowan CE, Monis A, Bacon BR, et al. Hepatology. 2013 Jan 12. doi: 10.1002/hep.26246. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23315914

Liver Cancer

Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: Effect of patient and non-patient factors. Davila JA, Kramer JR, Duan Z, et al. Hepatology. 2013 Jan 28. doi: 10.1002/hep.26287. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23359313

The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. Hepatology. 2013 Jan;57(1):249-57. doi: 10.1002/hep.25800.

http://www.ncbi.nlm.nih.gov/pubmed/22532055

Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. Lee CH, Hsieh SY, Chang CJ, Lin YJ. J Gastroenterol Hepatol. 2013 Jan;28(1):122-7. doi: 10.1111/j.1440-1746.2012.07289.x.

http://www.ncbi.nlm.nih.gov/pubmed/23034166

Infection with Hepatitis C Virus is an Adverse Prognostic Factor after Liver Resection for Early-stage Hepatocellular Carcinoma : Implications for the Management of Hepatocellular Carcinoma Eligible for Liver Transplantation. Chirica M, Tranchart H, Tan V, Faron M, Balladur P, Paye F. Ann Surg Oncol. 2013 Jan 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23338483

Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail? Singal AG, Nehra M, Adams-Huet B, et al. Am J Gastroenterol. 2013 Jan 22. doi: 10.1038/ajg.2012.449. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23337478

Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Tanaka S, Miyanishi K, Kobune M, et al. J Gastroenterol. 2013 Jan 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23329365

Soluble receptor for advanced glycation end products and risk of liver cancer.

Moy KA, Jiao L, Freedman ND, et al. Hepatology. 2013 Jan 16. doi: 10.1002/hep.26264. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23325627

Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Li T, Qin LX, Gong X, et al. Cancer. 2013 Jan 1;119(1):126-35. doi: 10.1002/cncr.27697. Epub 2012 Jun 26.

http://www.ncbi.nlm.nih.gov/pubmed/22736338

Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. Hosokawa T, Kurosaki M, Tsuchiya K, et al. World J Gastroenterol. 2013 Jan 14;19(2):249-57. doi: 10.3748/wjg.v19.i2.249.

http://www.ncbi.nlm.nih.gov/pubmed/23345948